Cybin Inc. Common Stock (HELP) Stock Score, Valuation & Financial Research

Cybin Inc. Common Stock is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for HELP

Cybin Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 10.76. These figures are a research snapshot, not a buy or sell recommendation.

What Cybin Inc. Common Stock does

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

Cybin Inc. (doing business as Helus Pharma) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics. The company does not currently generate revenue from product sales and relies on capital raises and financing activities to fund its research, development, and clinical trial operations.

Products and services

  • The company is developing a pipeline of proprietary psychedelic-based drug candidates, including CYB003 and CYB004, targeting mental health conditions such as major depressive disorder and generalized anxiety disorder.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party contract research organizations to conduct clinical trials and manage regulatory processes. Source

Business relationships and partnerships

  • Catalent, Inc. — Drug development agreement for the development and manufacturing of psychedelic drug candidates. Source

Business strengths to evaluate

  • Proprietary drug development pipeline Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source · Catalent, Inc.

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

HELP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 10.76
Market capitalization:
666.95M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -183.27M
Free cash flow:
USD -133.79M
Cash:
USD 166.17M
Total debt:
USD 0.00
EPS:
USD -5.51

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -133.79M, negative for the stored period.
  • The balance sheet shows USD 166.17M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 166.17M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for HELP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving HELP's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can HELP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is HELP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for HELP to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of HELP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research HELP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.